Internal Medicine, Pulmonary Disease · Guaynabo, PR
NPI
1003808742
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
0
Medicare group memberships
Hospitals
2
Hospital affiliations
Ave San Patricio # 101, Maramar Plaza Suite 1240
Guaynabo, PR, 00968
Phone (787) 508-5445
Medicare paid, 2024
$30K
518 services
Medicare patients, 2024
118
Average age 76
Drug cost, 2024
$8.3M
2,214 prescriptions
Company payments, 2025
$2,000
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elba R Martin Reyes was code 99214 (office e&m - established), 111 times for 56 patients. In total Elba R Martin Reyes billed 518 services in 23 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 111 | 56 | $87.92 | $9,759 |
| 99232 Hospital E&M - Subsequent | Facility | 110 | 31 | $61.02 | $6,712 |
| 94375 Pulmonary Function Testing | Office | 71 | 46 | $28.15 | $1,999 |
| 94200 Pulmonary Function Testing | Office | 65 | 44 | $11.12 | $723 |
| 99222 Hospital E&M - Initial | Facility | 26 | 24 | $101.09 | $2,628 |
| 94729 Pulmonary Function Testing | Office | 20 | 19 | $39.09 | $782 |
| 94727 Pulmonary Function Testing | Office | 20 | 19 | $32.48 | $650 |
| 95811 Sleep Study | Facility | 18 | 17 | $93.19 | $1,677 |
| 94640 Treatment - Miscellaneous | Office | 17 | 14 | $5.91 | $100 |
By year: 2022 $60K for 744 services; 2023 $35K for 577 services; 2024 $30K for 518 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elba R Martin Reyes prescribed most often to Medicare patients was Adempas (Riociguat), with 271 prescriptions and refills. In total Elba R Martin Reyes wrote 2,214 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Adempas Riociguat | 271 | 271 | 28 | $3.8M |
| Fluticasone Propionate Generic | 257 | 360 | 103 | $4,533 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 249 | 255 | 79 | $13K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 209 | 222 | 39 | $139K |
| Montelukast Sodium Generic | 155 | 191 | 57 | $1,390 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 102 | 118 | 31 | $22K |
| Opsumit Macitentan | 100 | 100 | Under 11 | $1.3M |
| Breo Ellipta Fluticasone/Vilanterol | 75 | 75 | 26 | $31K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 72 | 74 | 16 | $35K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 70 | 72 | 14 | $9,343 |
| Ofev Nintedanib Esylate | 64 | 64 | Under 11 | $833K |
| Azelastine-Fluticasone Azelastine/Fluticasone | 63 | 71 | 25 | $6,178 |
| Levalbuterol Tartrate Hfa Levalbuterol Tartrate | 57 | 58 | 24 | $3,356 |
| Symbicort Budesonide/Formoterol Fumarate | 51 | 53 | 24 | $12K |
| Uptravi Selexipag | 49 | 49 | Under 11 | $1.0M |
Brand drugs: 1,423 claims; generic drugs: 791 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elba R Martin Reyes $2,000 ($2,000 in general payments such as food, travel and fees) from 16 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $246.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $246 |
| Genzyme Corporation SNY | 6 | $218 |
| ANI Pharmaceuticals, Inc. ANIP | 4 | $203 |
| Merck Sharp & Dohme LLC MRK | 8 | $173 |
| Actelion Pharmaceuticals US, Inc. JNJ | 1 | $148 |
| United Therapeutics Corporation UTHR | 6 | $143 |
| Janssen Pharmaceuticals, Inc JNJ | 6 | $138 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $126 |
| Lilly USA, LLC LLY | 1 | $125 |
| Viatris Specialty LLC | 5 | $117 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.